Brief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
05/10/2026 21:03
BRIEF-Oric® Pharmaceuticals Announces Agreement With Cancer Research UK Oct 5 (Reuters) - ORIC Pharmaceuticals, Inc. ORIC.O:
ORIC® PHARMACEUTICALS ANNOUNCES AGREEMENT WITH CANCER RESEARCH UK TO ADVANCE A POTENTIAL FIRST-IN-CLASS CIP2A-TARGETED THERAPY INTO CLINICAL DEVELOPMENT
ORIC PHARMACEUTICALS, - RETAINS OPTION TO REACQUIRE ORIC-259 RIGHTS AFTER PHASE 1/2 DATA
ORIC PHARMACEUTICALS, - CANCER RESEARCH UK TO FULLY FUND AND EXECUTE EARLY CLINICAL DEVELOPMENT OF ORIC-259
Source text: ID:nGNXblw2lK
Further company coverage: ORIC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows